Impact of Hyaluronic Acid and Other Re-Epithelializing Agents in Periodontal Regeneration: A Molecular Perspective
Abstract
:1. Introduction
2. Materials and Methods
Inclusion and Exclusion Criteria
3. Molecular Mechanisms of Hyaluronic Acid
3.1. Structure and Properties of Hyaluronic Acid
3.2. Interaction of Hyaluronic Acid with Epithelial and Connective Tissue Cells
3.3. Role of Hyaluronic Acid in Cell Migration, Proliferation, and Differentiation
3.4. Signaling Pathways Modulated by Hyaluronic Acid in Periodontal Regeneration
- CD44, which functions as a receptor for collagen, fibronectin, osteopontin, and HA present in the ECM. The interactions between CD44 and these ECM components transduce several signaling pathways. The cytoplasmic domain of CD44 is bound to the actin cytoskeleton and interacts with cytoskeleton-associated proteins such as ezrin/radixin/moesin (ERM) and ankyrin [25], resulting in cytoskeleton activation and causing several biological functions including cell adhesion, proliferation, and migration [26]. The stimulation of CD44 triggers a signaling cascade associated with two tyrosine kinases: p185 human epidermal growth factor receptor 2 (HER2) and c-Src kinase. The activation of p185HER2 leads to increased cell growth, whereas c-Src kinase activity is responsible for the phosphorylation of cytoskeleton proteins and the induction of cell motility. In addition to the phosphoinositide-3 kinase/phosphoinositide-dependent kinase 1/protein kinase B pathway, Ras protein signaling pathways are also involved in CD44 cytoplasmic signaling [27].
- Other cell surface receptors including RHAMM (Receptor for Hyaluronan-Mediated Motility), LYVE-1 (Lymphatic Vessel Endothelial Hyaluronan Receptor 1), and Layilin, are known to bind to HA. RHAMM is a protein involved in the regulation of cell migration and proliferation, mainly through interactions with hyaluronic acid. It is associated with processes such as wound healing and tumor progression, contributing to the growth and spread of cancer cells [28]. Several kinases, such as Src kinase, focal adhesion kinase, extracellular-signal-regulated kinases (ERK) 1/2, and protein kinase C, are involved in RHAMM signaling. This receptor is also associated with the Ras protein and the Ras signaling pathway [27]. LYVE-1 is a receptor present in the endothelial cells of lymphatic vessels and is involved in the transport of hyaluronic acid. It plays a key role in the regulation of lymphatic drainage and the migration of immune cells. Layilin is a membrane protein that regulates the interaction of cells with their surroundings, influencing processes such as cell migration and adhesion. The HA-induced regulation of cellular function via HA receptors varies depending on differences in the cell type, cell origin, and HA size [28].
4. Molecular Mechanisms of Re-Epithelizing Agents
4.1. Growth Factors
- Platelet-derived growth factor (PDGF): PDGF is regarded as one of the principal wound-healing hormones. It was discovered by Lynch et al. [30] to promote the regeneration of bone, cementum, and periodontal ligament in the late 1980s. PDGF is composed of two disulfide-bonded polypeptide chains that are encoded by two different genes, namely, PDGF-A and PDGF-B. In nature, PDGF can exist as a homodimer—PDGF-AA and PDGF-BB. PDGF is an important stimulator of cell chemotaxis, proliferation, and matrix synthesis that exhibits anti-apoptosis activity. PDGF is involved in almost all types of wound healing by virtue of platelets and its dual role as a reservoir of growth factors and a hemostasis factor. PDGF stimulates the influx of neutrophils to the wound site [31].
- Insulin-like growth factor: IGFs constitute a family of single-chain proteins that share 49% homology with pro-insulin. Two well-described members of this group are IGF-1 and IGF-2, which are similar in structure and function but are independently regulated. The IGF family includes three ligands and three cell surface receptors, namely, insulin, IGF-I, and IGF-II and Insulin, IGF-1, and IGF–l-mannose G-phosphate receptors, respectively. They have at least six high-affinity IGF-binding proteins which bind circulating IGFs and modulate their biological activity. Both IGF-I and IGF-II are synthesized as large precursor molecules (195 and 156 aa), which are proteolytically cleaved to release the biologically active monomeric proteins. Insulin-like growth factor-I is found in substantial levels in platelets and is released during clotting along with the other growth factors present in platelets. IGF-I released from platelets or produced by fibroblasts may promote the migration of vascular endothelial cells into the wound area, resulting in increased neovascularization. It also stimulates the mitosis of many cells in vitro such as fibroblasts, osteocytes, and chondrocytes [32].
- Transforming growth factors (TGFs): TGFs are a family of structurally and functionally unrelated proteins that have been isolated from normal and neoplastic tissues. The two main polypeptides are TGF-α and TGF-β. TGF-α is a polypeptide sharing 80% homology with epidermal growth factor (EGF) and it binds to the cellular EGF receptor. TGF-β acts as a progression factor for fibroblasts. TGF-β appears to be a major regulator of cell replication and differentiation. It is bifunctional or pleiotropic and can therefore stimulate or inhibit cell growth. TGF-β can also modulate other growth factors such as PDGF, TGF-α, EGF, and fibroblast growth factor (FGF), possibly by altering their cellular response or by inducing their expression [33]. It has a potent effect on matrix synthesis, giving rise to the increased production of collagen and fibronectin and the decreased production of matrix-degrading enzymes [31].
- BMPs (bone morphogenic proteins): BMPs are a group of osteoinductive proteins obtained from nonmineralized bone matrix; they can stimulate the differentiation of pluripotent mesenchymal cells to osteoprogenitor cells. Currently, there are more than 30 identified BMPs, but the most recent studies on periodontal regeneration have been conducted using GDF-5 and BMP-7. They are responsible for several biological activities involving tissue morphogenesis, regeneration, healing, and cell differentiation processes [34]. GDF-5 induces chondrogenesis and osteogenesis in vitro and in vivo, supported by a carrier agent. The bioresorbable polymer polylactic-glycolic acid (PLGA) and specific additives, designed as carriers for rhGDF-5 in minimally invasive regenerative procedures, create an ideal matrix to enhance natural wound healing and the action of rhGDF-5 [35]. BMP-7 is a potent bone-inducing factor and was shown to promote periodontal regeneration in vivo and in vitro. BMP-7 treatment markedly stimulated cementoblast-mediated biomineralization in vitro compared to untreated cells [36].
4.2. Enamel Matrix Proteins (EMDs)
4.3. Blood-Derived Products
4.4. Engineered Tissues
4.5. Stem Cell
4.6. Biomaterials
- Barrier membranes: GTR/GBR membranes prevent unwanted cell invasion and maintain mechanical stability to support periodontal tissue regeneration. They are categorized into resorbable and non-resorbable membranes. The most common resorbable membranes are made of collagen and are degraded enzymatically by collagenases, polymorphonuclear/macrophage leukocyte-derived enzymes, and bacterial proteases [47]. Non-absorbable barrier membranes are made of expanded polytetrafluoroethylene (ePTFE), a material that exhibits excellent biocompatibility and mechanical stability [48]. Since PTFE is a non-absorbable membrane, patients require a second surgery to retrieve it, which increases the risk of site morbidity [49].
- Bone graft: Bone grafts are commonly used with barrier membranes to obtain periodontal regeneration and the reconstruction of the alveolar ridge. They can be divided into autografts, allografts, xenografts, and alloplastic materials [50]. Autografts are taken from the patient’s body and are considered the gold standard. Allografts are harvested from one individual for transplantation to another [51]. Xenografts are obtained from different species and prepared by various procedures. Two of the most used xenografts in dentistry are deproteinated bovine bone matrix (DBBM) and demineralized porcine bone matrix (DPBM) [52]. Alloplastic grafts are synthetic biomaterials and the most commonly used ones are HA, tricalcium phosphates (TCPs), and bioactive glasses [51].
4.7. Antimicrobial Agents
- CHX: CHX has been shown to be an effective agent against oral biofilms and has antimicrobial properties against both Gram-positive and Gram-negative bacteria, yeasts, and viruses [53]. The mechanism of action (MOA) of CHX begins with the rapid attraction of the cationic CHX molecule to the surface of the bacterial cell, which is negatively charged and contains phosphate and sulfate groups [6]. This causes specific and strong adsorption to the phosphate-containing components that form the surface of the bacterial cell. Penetration through the bacterial cell wall occurs by passive diffusion, damaging the cytoplasmic membrane [54]. This process allows CHX to penetrate the inner cell membrane, increasing permeability. As a result, there is leakage of low-molecular-weight molecules and cytoplasmic components from the microorganism, such as potassium ions, which leads to the inhibition of the activity of some enzymes associated with the cytoplasmic membrane [55]. At this point, the antimicrobial action of CHX remains in the bacteriostatic phase but can be reversed if CHX is removed. If the concentration of CHX remains stable over time or increases, irreversible cellular damage occurs, activating a bactericidal effect. In the bactericidal phase, coagulation and cytoplasmic precipitation occur through the formation of complexes with phosphorylated compounds, such as adenosine triphosphate and nucleic acids [54]. Due to the negative charge of most oral surfaces, such as mucous membranes, teeth, and salivary glycoproteins, cationic CHX molecules adhere well to these surfaces. This interferes with bacterial adhesion and ensures substantivity for up to 12 h [55,56]. Several studies have shown that CHX mouthwash with concentrations between 0.1% and 0.2% has significant anti-inflammatory and anti-plaque effects on the gingiva and teeth [57,58,59]. However, CHX has adverse effects such as xerostomia, hypogeusia, and discoloration of the tongue, tartar, and tooth staining with long-term use. Less common adverse effects include swelling of the parotid gland, oral paresthesia, glossodynia, and desquamation of the oral mucosa [60].
- Metronidazole: Metronidazole is a synthetic antibiotic derived from azomycin and it is very effective in treating infections caused by anaerobic or microaerophilic microorganisms [61]. The mechanism of action of metronidazole consists of crossing the cell membrane of the target microorganism by passive diffusion. Once inside the cell, the nitro group of metronidazole is reduced to nitro radicals by ferredoxin or flavodoxin. Its selectivity for anaerobic bacteria and microaerophilic microorganisms arises from the redox potential of their electron transport systems, which are responsible for the reduction of nitro groups and the generation of toxic metabolites. These metabolites, such as N-(2-hydroxyethyl) oxamic acid and acetamide, can interact with DNA and form covalent bonds with guanosine, thereby impairing DNA replication and function [62]. Due to the low rate of bacterial resistance to metronidazole [63] and its spectrum of action against Gram-negative bacteria associated with periodontal diseases, this appears to be a promising drug for the treatment of periodontitis [64].
- Minocycline, doxycycline, and tetracycline: These substances are greatly effective in the inhibition of Gram-negative facultative anaerobes [65] and exhibit anti-collagenase activity [66]. Tetracyclines are bacteriostatic antibiotics that exert their antibacterial activity by inhibiting microbial protein synthesis. Doxycycline and minocycline are more lipophilic than tetracycline, allowing them to pass directly through the bacterial cell membrane’s lipid bilayer. Once across this layer, an energy-dependent mechanism transports the drug through the inner cytoplasmic membrane. Inside the cell, tetracycline specifically binds to the 30S ribosomal subunit. This binding appears to prevent the aminoacyl-tRNA from attaching to the mRNA ribosomal receptor site, thereby blocking the addition of the amino group to the growing peptide chain [66]. Minocycline is better for its effect on adhesion and diffusion of fibroblasts, crucial for tissue regeneration [67]. Doxycycline has a greater protein-binding capacity, a longer half-life, and is the most potent tetracycline for collagenase inhibition [66].
4.8. Anti-Inflammatory Agents
5. Crosstalk Between Epithelial and Connective Tissue Cells
5.1. Interactions Between Epithelial and Connective Tissue Cells in Periodontal Tissues
5.2. Impact of Hyaluronic Acid and Re-Epithelizing Agents on Epithelial–Connective Tissue Crosstalk
5.3. Effects of Crosstalk on Periodontal Regeneration Processes
5.4. Molecular Mechanisms Underlying Epithelial–Connective Tissue Interactions in Periodontal Regeneration
- Integrins and cadherins: Integrins such as α6β4 and αvβ6 are very relevant in connective tissue–epithelium interactions, as they influence cell migration and proliferation during periodontal regeneration. Cadherins, on the other hand, are cell–cell adhesion molecules that stabilize epithelial junctions and modulate epithelial–connective tissue interactions.
- Cytokines and growth factors: Several growth factors, such as EGF, TGF-β, and PDGF, are involved in epithelial–connective tissue interactions. These factors modulate cell proliferation, differentiation, and matrix production, contributing to tissue regeneration [97].
6. Clinical Implications and Future Perspectives
6.1. Clinical Implications
- HA: Its numerous properties have been studied as a possible adjuvant in NSPT. Its application has been tested in various periodontal conditions [102,103,104], including the treatment of infraosseous defects, where a reduction in PD and an increase in CAL were recorded [105]. Among the most important properties is its regenerative capacity, linked to its osteoinductive effect, which promotes the migration of endothelial cells that form a network for the deposition of bone tissue [106].
- Growth factors: Plasma rich in growth factors (PRGF) is an autologous platelet concentrate that locally releases growth factors and cytokines, supporting hemostasis and the regeneration of soft and bone tissues. It promotes wound healing, epithelialization, and may aid in the early resolution of chronic inflammatory lesions, such as periodontal pockets, making it useful in non-surgical periodontal therapy [107].
- EMDs: EMDs are used as adjunctive agents during periodontal therapy to promote the regeneration of both soft and hard tissues. They have demonstrated benefits such as reducing probing pocket depth (PPD) and increasing the clinical attachment level (CAL) [108].
- Blood-derived products: They are used in periodontology because they facilitate the regeneration of dental support tissues, promoting tooth retention by reconstructing the periodontium, collagen fibers, and alveolar bone [109].
- Engineered tissues, stem cells, and biomaterials: The main goal of this technique is to restore the function and structure of the tooth’s supporting tissues, which include the periodontal ligament, root cementum, and alveolar bone [110]. However, stem cell therapies and tissue engineering in the field of periodontology are still in their early stages.
- Antimicrobial agents: The local application of antimicrobial agents in the oral cavity in patients suffering from periodontitis offers a targeted and localized therapy. This approach achieves a drug concentration at the site of periodontal pockets that exceeds the minimum inhibitory concentration (MIC). This concentration remains high for up to several weeks, resulting in prolonged effectiveness over time and reducing the need for frequent administration [111]. CHX-based mouthwash, with concentrations between 0.1% and 0.2%, presents significant anti-plaque effects when used daily for a period of 2 weeks, even in the absence of mechanical cleaning. Furthermore, it appears to be a valid long-term complement to oral hygiene, if used at regular intervals of 4–6 weeks up to 6 months [112]. Among the antimicrobials used for the treatment of periodontitis, metronidazole in gel composition is indicated for its narrow spectrum of action against obligate anaerobes and for its fewer side effects [113], and tetracyclines for their MMP inhibitory capacity of plaque biofilm-induced degradation of periodontal structures. Among the tetracyclines, the favorite is doxycycline, which is safer and has superior pharmacokinetics [114].
- Anti-inflammatory agents: The use of NSAIDs in the treatment of periodontitis is still poorly defined, with effects on periodontal health that have not been fully clarified. Furthermore, since conventional periodontal therapies have been shown to be effective in resolving inflammation and stopping tissue destruction [115], the use of NSAIDs as an additional therapy is not necessary [72].
6.2. Future Perspectives
7. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Papapanou, P.N.; Sanz, M.; Buduneli, N.; Dietrich, T.; Feres, M.; Fine, D.H.; Flemmig, T.F.; Garcia, R.; Giannobile, W.V.; Graziani, F.; et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J. Periodontol. 2018, 89, S173–S182. [Google Scholar] [CrossRef] [PubMed]
- Nuñez, J.; Vignoletti, F.; Caffesse, R.G.; Sanz, M. Cellular therapy in periodontal regeneration. Periodontol. 2000 2019, 79, 107–116. [Google Scholar] [CrossRef] [PubMed]
- Graves, D.; Cochran, D. The Contribution of Interleukin-1 and Tumor Necrosis Factor to Periodontal Tissue Destruction. J. Periodontol. 2003, 74, 391–401. [Google Scholar] [CrossRef] [PubMed]
- Apatzidou, D.A.; Kinane, D.F. Nonsurgical Mechanical Treatment Strategies for Periodontal Disease. Dent. Clin. N. Am. 2010, 54, 1–12. [Google Scholar] [CrossRef]
- Tomasi, C.; Abrahamsson, K.H.; Apatzidou, D. Subgingival instrumentation. Periodontol. 2000 2023. [Google Scholar] [CrossRef]
- Lukomska-Szymańska, M.; Sokołowski, J.; Łapińska, B. Chlorhexidine—Mechanism of Action and Its Application to Dentistry. jstoma 2017, 70, 405–417. [Google Scholar] [CrossRef]
- Dahiya, P.; Kamal, R. Hyaluronic Acid: A Boon in Periodontal Therapy. N. Am. J. Med. Sci. 2013, 5, 309–315. [Google Scholar] [CrossRef]
- Iaconisi, G.N.; Lunetti, P.; Gallo, N.; Cappello, A.R.; Fiermonte, G.; Dolce, V.; Capobianco, L. Hyaluronic Acid: A Powerful Biomolecule with Wide-Ranging Applications—A Comprehensive Review. Int. J. Mol. Sci. 2023, 24, 10296. [Google Scholar] [CrossRef]
- Weigel, P.H.; Hascall, V.C.; Tammi, M. Hyaluronan Synthases. J. Biol. Chem. 1997, 272, 13997–14000. [Google Scholar] [CrossRef]
- Itano, N.; Sawai, T.; Yoshida, M.; Lenas, P.; Yamada, Y.; Imagawa, M.; Shinomura, T.; Hamaguchi, M.; Yoshida, Y.; Ohnuki, Y.; et al. Three Isoforms of Mammalian Hyaluronan Synthases Have Distinct Enzymatic Properties. J. Biol. Chem. 1999, 274, 25085–25092. [Google Scholar] [CrossRef]
- Tavianatou, A.G.; Caon, I.; Franchi, M.; Piperigkou, Z.; Galesso, D.; Karamanos, N.K. Hyaluronan: Molecular Size-Dependent Signaling and Biological Functions in Inflammation and Cancer. FEBS J. 2019, 286, 2883–2908. [Google Scholar] [CrossRef]
- Abatangelo, G.; Vindigni, V.; Avruscio, G.; Pandis, L.; Brun, P. Hyaluronic Acid: Redefining Its Role. Cells 2020, 9, 1743. [Google Scholar] [CrossRef] [PubMed]
- Miglani, A.; Vishnani, R.; Reche, A.; Buldeo, J.; Wadher, B. Hyaluronic Acid: Exploring Its Versatile Applications in Dentistry. Cureus 2023, 15, e46349. [Google Scholar] [CrossRef]
- Bansal, J.; Kedige, S.D.; Anand, S. Hyaluronic Acid: A Promising Mediator for Periodontal Regeneration. Indian J. Dent. Res. 2010, 21, 575–578. [Google Scholar] [CrossRef]
- Oksala, O.; Salo, T.; Tammi, R.; Häkkinen, L.; Jalkanen, M.; Inki, P.; Larjava, H. Expression of Proteoglycans and Hyaluronan During Wound Healing. J. Histochem. Cytochem. 1995, 43, 125–135. [Google Scholar] [CrossRef] [PubMed]
- Weigel, P.; Frost, S.; Mcgary, C.; Leboeuf, R. The Role of Hyaluronic-Acid in Inflammation and Wound-Healing. Int. J. Tissue React. 1988, 10, 355–365. [Google Scholar]
- Toole, B.P. Hyaluronan in morphogenesis. Semin. Cell Dev. Biol. 2001, 12, 79–87. [Google Scholar] [CrossRef]
- Mendes, R.M.; Silva, G.A.; Lima, M.F.; Calliari, M.V.; Almeida, A.P.; Alves, J.B.; Ferreira, A.J. Sodium Hyaluronate Accelerates the Healing Process in Tooth Sockets of Rats. Arch. Oral Biol. 2008, 53, 1155–1162. [Google Scholar] [CrossRef]
- Hunt, D.R.; Jovanovic, S.A.; Wikesjö, U.M.; Wozney, J.M.; Bernard, G.W. Hyaluronan Supports Recombinant Human Bone Morphogenetic Protein-2 Induced Bone Reconstruction of Advanced Alveolar Ridge Defects in Dogs. A Pilot Study. J. Periodontol. 2001, 72, 651–658. [Google Scholar] [CrossRef] [PubMed]
- Yang, H.; Song, L.; Zou, Y.; Sun, D.; Wang, L.; Yu, Z.; Guo, J. Role of Hyaluronic Acids and Potential as Regenerative Biomaterials in Wound Healing. ACS Appl. Bio Mater. 2021, 4, 311–324. [Google Scholar] [CrossRef]
- Landén, N.X.; Li, D.; Ståhle, M. Transition from Inflammation to Proliferation: A Critical Step During Wound Healing. Cell. Mol. Life Sci. 2016, 73, 3861–3885. [Google Scholar] [CrossRef]
- West, D.C.; Hampson, I.N.; Arnold, F.; Kumar, S. Angiogenesis Induced by Degradation Products of Hyaluronic Acid. Science 1985, 228, 1324–1326. [Google Scholar] [CrossRef] [PubMed]
- Stern, R.; Asari, A.A.; Sugahara, K.N. Hyaluronan Fragments: An Information-Rich System. Eur. J. Cell Biol. 2006, 85, 699–715. [Google Scholar] [CrossRef] [PubMed]
- Rooney, P.; Wang, M.; Kumar, P.; Kumar, S. Angiogenic Oligosaccharides of Hyaluronan Enhance the Production of Collagens by Endothelial Cells. J. Cell Sci. 1993, 105 Pt 1, 213–218. [Google Scholar] [CrossRef] [PubMed]
- Hirao, M.; Sato, N.; Kondo, T.; Yonemura, S.; Monden, M.; Sasaki, T.; Takai, Y.; Tsukita, S. Regulation Mechanism of ERM (ezrin/radixin/moesin) Protein/Plasma Membrane Association: Possible Involvement of Phosphatidylinositol Turnover and Rho-Dependent Signaling Pathway. J. Cell Biol. 1996, 135, 37–51. [Google Scholar] [CrossRef]
- Lokeshwar, V.B.; Fregien, N.; Bourguignon, L.Y. Ankyrin-Binding Domain of CD44(GP85) is Required for the Expression of Hyaluronic Acid-Mediated Adhesion Function. J. Cell Biol. 1994, 126, 1099–1109. [Google Scholar] [CrossRef] [PubMed]
- Litwiniuk, M.; Krejner, A.; Speyrer, M.S.; Gauto, A.R.; Grzela, T. Hyaluronic Acid in Inflammation and Tissue Regeneration. Wounds 2016, 28, 78–88. [Google Scholar] [PubMed]
- Shimabukuro, Y.; Terashima, H.; Takedachi, M.; Maeda, K.; Nakamura, T.; Sawada, K.; Kobashi, M.; Awata, T.; Oohara, H.; Kawahara, T.; et al. Fibroblast Growth Factor-2 Stimulates Directed Migration of Periodontal Ligament Cells via PI3K/AKT Signaling and CD44/Hyaluronan Interaction. J. Cell. Physiol. 2011, 226, 809–821. [Google Scholar] [CrossRef]
- Howell, T.H.; Martuscelli, G.; Oringer, J. Polypeptide Growth Factors for Periodontal Regeneration. Curr. Opin. Periodontol. 1996, 3, 149–156. [Google Scholar]
- Lynch, S.E.; de Castilla, G.R.; Williams, R.C.; Kiritsy, C.P.; Howell, T.H.; Reddy, M.S.; Antoniades, H.N. The Effects of Short-Term Application of a Combination of Platelet-Derived and Insulin-Like Growth Factors on Periodontal Wound Healing. J. Periodontol. 1991, 62, 458–467. [Google Scholar] [CrossRef]
- Raja, S.; Byakod, G.; Pudakalkatti, P. Growth Factors in Periodontal Regeneration. Int. J. Dent. Hyg. 2009, 7, 82–89. [Google Scholar] [CrossRef] [PubMed]
- Bennett, N.T.; Schultz, G.S. Growth factors and wound healing: Biochemical Properties of Growth Factors and Their Receptors. Am. J. Surg. 1993, 165, 728–737. [Google Scholar] [CrossRef]
- Caffesse, R.G.; Quiñones, C.R. Polypeptide Growth Factors and Attachment Proteins in Periodontal Wound Healing and Regeneration. Periodontol. 2000 1993, 1, 69–79. [Google Scholar] [CrossRef] [PubMed]
- Díaz-Sánchez, R.-M.; Yáñez-Vico, R.-M.; Fernández-Olavarría, A.; Mosquera-Pérez, R.; Iglesias-Linares, A.; Torres-Lagares, D. Current Approaches of Bone Morphogenetic Proteins in Dentistry. J. Oral Implant. 2015, 41, 337–342. [Google Scholar] [CrossRef]
- Herberg, S.; Siedler, M.; Pippig, S.; Schuetz, A.; Dony, C.; Kim, C.; Wikesjö, U.M.E. Development of an Injectable Composite as a Carrier for Growth Factor-Enhanced Periodontal Regeneration. J. Clin. Periodontol. 2008, 35, 976–984. [Google Scholar] [CrossRef]
- Hakki, S.S.; Foster, B.L.; Nagatomo, K.J.; Bozkurt, S.B.; Hakki, E.E.; Somerman, M.J.; Nohutcu, R.M. Bone Morphogenetic Protein-7 Enhances Cementoblast Function In Vitro. J. Periodontol. 2010, 81, 1663–1674. [Google Scholar] [CrossRef] [PubMed]
- Amin, H.D.; Olsen, I.; Knowles, J.; Dard, M.; Donos, N. Interaction of Enamel Matrix Proteins with Human Periodontal Ligament Cells. Clin. Oral Investig. 2015, 20, 339–347. [Google Scholar] [CrossRef]
- Lyngstadaas, S.P.; Wohlfahrt, J.C.; Brookes, S.J.; Paine, M.L.; Snead, M.L.; Reseland, J.E. Enamel Matrix Proteins; Old Molecules for new Applications. Orthod. Craniofac. Res. 2009, 12, 243–253. [Google Scholar] [CrossRef]
- Fincham, A.; Moradian-Oldak, J.; Simmer, J.; Sarte, P.; Lau, E.; Diekwisch, T.; Slavkin, H. Self-Assembly of a Recombinant Amelogenin Protein Generates Supramolecular Structures. J. Struct. Biol. 1994, 112, 103–109. [Google Scholar] [CrossRef]
- Lyngstadaas, S.P.; Lundberg, E.; Ekdahl, H.; Andersson, C.; Gestrelius, S. Autocrine Growth Factors in Human Periodontal ligament Cells Cultured on Enamel Matrix Derivative. J. Clin. Periodontol. 2001, 28, 181–188. [Google Scholar] [CrossRef]
- Baniulyte, G.; Ali, K.; Burns, L. Guided Tissue Regeneration Techniques Involving Blood-Derived Products in Periradicular surgery: A Systematic Review and Meta-Analysis Protocol. JBI Evid. Synth. 2021, 19, 3378–3383. [Google Scholar] [CrossRef] [PubMed]
- Balaban, Y.E.; Akbaba, S.; Bozkurt, S.B.; Buyuksungur, A.; Akgun, E.E.; Gonen, Z.B.; Salkin, H.; Tezcaner, A.; Hakki, S.S. Local Application of Gingiva-Derived Mesenchymal Stem Cells on Experimental Periodontitis in Rats. J. Periodontol. 2024, 95, 456–468. [Google Scholar] [CrossRef] [PubMed]
- Srisuwan, T.; Tilkorn, D.J.; Wilson, J.L.; Morrison, W.A.; Messer, H.M.; Thompson, E.W.; Abberton, K.M. Molecular Aspects of Tissue Engineering in the Dental Field. Periodontol. 2000 2006, 41, 88–108. [Google Scholar] [CrossRef]
- Singh, S.; Singh, A.; Singh, S.; Singh, R. Application of PRF in Surgical Management of Periapical Lesions. Natl. J. Maxillofac. Surg. 2013, 4, 94–99. [Google Scholar] [CrossRef] [PubMed]
- Wen, W.; Pang, Y.; Tian, Y.; Xu, C.; Wang, J.; Wu, Y.; Xie, X. Osteogenic Mesenchymal Stem Cells/Progenitors in the Periodontium. Oral Dis. 2024, 30, 914–920. [Google Scholar] [CrossRef] [PubMed]
- Xu, X.-Y.; Li, X.; Wang, J.; He, X.-T.; Sun, H.-H.; Chen, F.-M. Concise Review: Periodontal Tissue Regeneration Using Stem Cells: Strategies and Translational Considerations. Stem Cells Transl. Med. 2018, 8, 392–403. [Google Scholar] [CrossRef]
- Chen, F.-M.; Sun, H.-H.; Lu, H.; Yu, Q. Stem Cell-Delivery Therapeutics for Periodontal Tissue Regeneration. Biomaterials 2012, 33, 6320–6344. [Google Scholar] [CrossRef]
- Lee, J.H.; Yi, G.S.; Lee, J.W.; Kim, D.J. Physicochemical Characterization of Porcine Bone-Derived Grafting Material and Comparison with Bovine Xenografts for Dental Applications. J. Periodontal Implant. Sci. 2017, 47, 388–401. [Google Scholar] [CrossRef] [PubMed]
- Mizraji, G.; Davidzohn, A.; Gursoy, M.; Gursoy, U.K.; Shapira, L.; Wilensky, A. Membrane Barriers for Guided Bone Regeneration: An Overview of Available Biomaterials. Periodontol. 2000 2023, 93, 56–76. [Google Scholar] [CrossRef]
- Deng, Y.; Liang, Y.; Liu, X. Biomaterials for Periodontal Regeneration. Dent. Clin. N. Am. 2022, 66, 659–672. [Google Scholar] [CrossRef]
- Sheikh, Z.; Hamdan, N.; Ikeda, Y.; Grynpas, M.; Ganss, B.; Glogauer, M. Natural Graft Tissues and Synthetic Biomaterials for Periodontal and Alveolar Bone Reconstructive Applications: A Review. Biomater. Res. 2017, 21, 9. [Google Scholar] [CrossRef] [PubMed]
- Nasr, H.F.; Aichelmann-Reidy, M.E.; Yukna, R.A. Bone and bone substitutes. Periodontol. 2000 1999, 19, 74–86. [Google Scholar] [CrossRef] [PubMed]
- Wade, W.G.; Addy, M. In vitro Activity of a Chlorhexidine–Containing Mouthwash Against Subgingival Bacteria. J. Periodontol. 1989, 60, 521–525. [Google Scholar] [CrossRef]
- Thangavelu, A.; Kaspar, S.; Kathirvelu, R.; Srinivasan, B.; Srinivasan, S.; Sundram, R. Chlorhexidine: An elixir for periodontics. J. Pharm. Bioallied Sci. 2020, 12, 57–59. [Google Scholar] [CrossRef] [PubMed]
- Zanatta, F.B.; Antoniazzi, R.P.; Rösing, C.K. The Effect of 0.12% Chlorhexidine Gluconate Rinsing on Previously Plaque-Free and Plaque-Covered Surfaces: A Randomized, Controlled Clinical Trial. J. Periodontol. 2007, 78, 2127–2134. [Google Scholar] [CrossRef] [PubMed]
- Solderer, A.; Kaufmann, M.; Hofer, D.; Wiedemeier, D.; Attin, T.; Schmidlin, P.R. Efficacy of Chlorhexidine Rinses After Periodontal or Implant Surgery: A Systematic Review. Clin. Oral Investig. 2018, 23, 21–32. [Google Scholar] [CrossRef]
- Aoun, G.; Saadeh, M.; Berberi, A. Effectiveness of Hexetidine 0.1% Compared to Chlorhexidine Digluconate 0.12% in Eliminating Candida Albicans Colonizing Dentures: A Randomized Clinical In Vivo Study. J. Int. Oral. Health 2015, 7, 5–8. [Google Scholar]
- Haydari, M.; Bardakci, A.G.; Koldsland, O.C.; Aass, A.M.; Sandvik, L.; Preus, H.R. Comparing the Effect of 0.06% -, 0.12% and 0.2% Chlorhexidine on Plaque, Bleeding and Side Effects in an Experimental Gingivitis Model: A Parallel Group, Double masked Randomized Clinical Trial. BMC Oral Health 2017, 17, 11. [Google Scholar] [CrossRef]
- Canullo, L.; Laino, L.; Longo, F.; Filetici, P.; D’onofrio, I.; Troiano, G. Does Chlorhexidine Prevent Complications in Extractive, Periodontal, and Implant Surgery? A Systematic Review and Meta-analysis with Trial Sequential Analysis. Int. J. Oral Maxillofac. Implant. 2020, 35, 1149–1158. [Google Scholar] [CrossRef]
- Deus, F.P.; Ouanounou, A. Chlorhexidine in Dentistry: Pharmacology, Uses, and Adverse Effects. Int. Dent. J. 2022, 72, 269–277. [Google Scholar] [CrossRef]
- Ceruelos, A.H.; Romero-Quezada, L.C.; Ledezma, J.C.R.; López-Contreras, L. Therapeutic Uses of Metronidazole and Its Side Effects: An Update. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 397–401. [Google Scholar]
- Müller, M. Mode of action of metronidazole on anaerobic bacteria and protozoa. Surgery 1983, 93, 165–171. [Google Scholar] [PubMed]
- Rams, T.E.; Dujardin, S.; Sautter, J.D.; Degener, J.E.; van Winkelhoff, A.J. Spiramycin resistance in human periodontitis microbiota. Anaerobe 2011, 17, 201–205. [Google Scholar] [CrossRef] [PubMed]
- Faveri, M.; Retamal-Valdes, B.; Mestnik, M.J.; de Figueiredo, L.C.; Barão, V.A.R.; Souza, J.G.S.; Duarte, P.M.; Feres, M. Microbiological Effects of Amoxicillin Plus Metronidazole in the Treatment of Young Patients with Stages III and IV Periodontitis: A Secondary Analysis from a 1-Year Double-Blinded Placebo-Controlled Randomized Clinical Trial. J. Periodontol. 2023, 94, 498–508. [Google Scholar] [CrossRef]
- Teles, R.P.; Teles, F.R.F. Antimicrobial Agents Used in the Control of Periodontal Biofilms: Effective Adjuncts to Mechanical Plaque Control? Braz. Oral Res. 2009, 23, 39–48. [Google Scholar] [CrossRef]
- Patil, V.; Mali, R.; Mali, A. Systemic Anti-Microbial Agents Used in Periodontal Therapy. J. Indian Soc. Periodontol. 2013, 17, 162–168. [Google Scholar] [CrossRef]
- O’Connor, B.; Newman, H.N.; Wilson, M. Susceptibility and Resistance of Plaque Bacteria to Minocycline. J. Periodontol. 1990, 61, 228–233. [Google Scholar] [CrossRef]
- Salvi, G.E.; Lang, N.P. The Effects of Non-Steroidal Anti-Inflammatory Drugs (Selective and Non-Selective) on the Treatment of Periodontal Diseases. Curr. Pharm. Des. 2005, 11, 1757–1769. [Google Scholar] [CrossRef]
- Meek, I.L.; Van de Laar, M.A.; Vonkeman, H.E. Non-Steroidal Anti-Inflammatory Drugs: An Overview of Cardiovascular Risks. Pharmaceuticals 2010, 3, 2146–2162. [Google Scholar] [CrossRef]
- Vane, J.R.; Botting, R.M. Anti-Inflammatory Drugs and Their Mechanism of Action. Inflamm. Res. 1998, 47 (Suppl. S2), 78–87. [Google Scholar] [CrossRef]
- Bacchi, S.; Palumbo, P.; Sponta, A.; Coppolino, M. Clinical Pharmacology of Non-Steroidal Anti-Inflammatory Drugs: A Review. Anti-Inflamm. Anti-Allergy Agents Med. Chem. 2012, 11, 52–64. [Google Scholar] [CrossRef] [PubMed]
- Ren, J.; Fok, M.R.; Zhang, Y.; Han, B.; Lin, Y. The Role of Non-Steroidal Anti-Inflammatory Drugs as Adjuncts to Periodontal Treatment and in Periodontal Regeneration. J. Transl. Med. 2023, 21, 149. [Google Scholar] [CrossRef] [PubMed]
- Bosshardt, D.D. Biological Mediators and Periodontal Regeneration: A Review of Enamel Matrix Proteins at the Cellular and Molecular Levels. J. Clin. Periodontol. 2008, 35, 87–105. [Google Scholar] [CrossRef]
- Zakrzewski, W.; Dobrzyński, M.; Szymonowicz, M.; Rybak, Z. Stem Cells: Past, Present, and Future. Stem Cell Res. Ther. 2019, 10, 68. [Google Scholar] [CrossRef]
- Sloan, P.; Picardo, M.; Schor, S.L. The Structure and Function of Oral Mucosa. Dent Update 1991, 18, 208–212. [Google Scholar]
- Bartold, P.M.; Narayanan, A.S. Molecular and Cell Biology of Healthy and Diseased Periodontal Tissues. Periodontol. 2000 2006, 40, 29–49. [Google Scholar] [CrossRef] [PubMed]
- Birkedal-Hansen, H. Role of Matrix Metalloproteinases in Human Periodontal Diseases. J. Periodontol. 1993, 64, 474–484. [Google Scholar] [CrossRef]
- Junxian, L.; Mehrabanian, M.; Mivehchi, H.; Banakar, M.; Etajuri, E.A. The Homeostasis and Therapeutic Applications of Innate and Adaptive Immune Cells in Periodontitis. Oral Dis. 2023, 29, 2552–2564. [Google Scholar] [CrossRef]
- Cekici, A.; Kantarci, A.; Hasturk, H.; Van Dyke, T.E. Inflammatory and Immune Pathways in the Pathogenesis of Periodontal Disease. Periodontol. 2000 2014, 64, 57–80. [Google Scholar] [CrossRef]
- Hernández-Monjaraz, B.; Santiago-Osorio, E.; Monroy-García, A.; Ledesma-Martínez, E.; Mendoza-Núñez, V.M. Mesenchymal Stem Cells of Dental Origin for Inducing Tissue Regeneration in Periodontitis: A Mini-Review. Int. J. Mol. Sci. 2018, 19, 944. [Google Scholar] [CrossRef]
- Tammi, R.; Pasonen-Seppänen, S.; Kolehmainen, E.; Tammi, M. Hyaluronan Synthase Induction and Hyaluronan Accumulation in Mouse Epidermis Following Skin Injury. J. Investig. Dermatol. 2005, 124, 898–905. [Google Scholar] [CrossRef]
- Werner, S.; Grose, R. Regulation of Wound Healing by Growth Factors and Cytokines. Physiol. Rev. 2003, 83, 835–870. [Google Scholar] [CrossRef] [PubMed]
- Wound Healing—Aiming for Perfect Skin Regeneration|Science. Available online: https://www.science.org/doi/10.1126/science.276.5309.75 (accessed on 4 September 2024).
- Day, A.J.; Sheehan, J.K. Hyaluronan: Polysaccharide Chaos to Protein Organisation. Curr. Opin. Struct. Biol. 2001, 11, 617–622. [Google Scholar] [CrossRef] [PubMed]
- Diller, R.B.; Tabor, A.J. The Role of the Extracellular Matrix (ECM) in Wound Healing: A Review. Biomimetics 2022, 7, 87. [Google Scholar] [CrossRef] [PubMed]
- Dopico, J.; Botelho, J.; Ouro, A.; Domínguez, C.; Machado, V.; Aramburu-Nuñez, M.; Custodia, A.; Blanco, T.; Vázquez-Reza, M.; Romaus-Sanjurjo, D.; et al. Association Between Periodontitis and Peripheral Markers of Innate Immunity Activation and Inflammation. J. Periodontol. 2023, 94, 11–19. [Google Scholar] [CrossRef]
- Kawano, Y.; Patrulea, V.; Sublet, E.; Borchard, G.; Iyoda, T.; Kageyama, R.; Morita, A.; Seino, S.; Yoshida, H.; Jordan, O.; et al. Wound Healing Promotion by Hyaluronic Acid: Effect of Molecular Weight on Gene Expression and In Vivo Wound Closure. Pharmaceuticals 2021, 14, 301. [Google Scholar] [CrossRef]
- Yin, L.; Li, X.; Hou, J. Macrophages in Periodontitis: A Dynamic Shift Between Tissue Destruction and Repair. Jpn. Dent. Sci. Rev. 2022, 58, 336–347. [Google Scholar] [CrossRef]
- Amato, M.; Santonocito, S.; Viglianisi, G.; Tatullo, M.; Isola, G. Impact of Oral Mesenchymal Stem Cells Applications as a Promising Therapeutic Target in the Therapy of Periodontal Disease. Int. J. Mol. Sci. 2022, 23, 13419. [Google Scholar] [CrossRef]
- Boyce, B.F.; Xing, L. Functions of RANKL/RANK/OPG in Bone Modeling and Remodeling. Arch. Biochem. Biophys. 2008, 473, 139–146. [Google Scholar] [CrossRef]
- Krishnan, V.; Bryant, H.U.; MacDougald, O.A. Regulation of Bone Mass by Wnt Signaling. J. Clin. Investig. 2006, 116, 1202–1209. [Google Scholar] [CrossRef]
- Frontiers|Wnt Signaling in Periodontal Disease. Available online: https://www.frontiersin.org/journals/dental-medicine/articles/10.3389/fdmed.2021.763308/full (accessed on 7 September 2024).
- Pagella, P.; De Vargas Roditi, L.; Stadlinger, B.; Moor, A.E.; Mitsiadis, T.A. Notch Signaling in the Dynamics of Perivascular Stem Cells and Their Niches. Stem Cells Transl. Med. 2021, 10, 1433–1445. [Google Scholar] [CrossRef] [PubMed]
- Zhang, F.-F.; Hao, Y.; Zhang, K.-X.; Yang, J.-J.; Zhao, Z.-Q.; Liu, H.-J.; Li, J.-T. Interplay Between Mesenchymal Stem Cells and Macrophages: Promoting Bone Tissue Repair. World J. Stem Cells 2024, 16, 375–388. [Google Scholar] [CrossRef] [PubMed]
- Yanagita, M.; Kojima, Y.; Kubota, M.; Mori, K.; Yamashita, M.; Yamada, S.; Kitamura, M.; Murakami, S. Cooperative Effects of FGF-2 and VEGF-A in Periodontal Ligament Cells. J. Dent. Res. 2014, 93, 89–95. [Google Scholar] [CrossRef] [PubMed]
- Ramadan, D.E.; Hariyani, N.; Indrawati, R.; Ridwan, R.D.; Diyatri, I. Cytokines and Chemokines in Periodontitis. Eur. J. Dent. 2020, 14, 483–495. [Google Scholar] [CrossRef] [PubMed]
- Bartold, P.M.; McCulloch, C.A.G.; Narayanan, A.S.; Pitaru, S. Tissue Engineering: A New Paradigm for Periodontal Regeneration Based on Molecular and Cell Biology. Periodontology 2000, 24, 253–269. [Google Scholar] [CrossRef]
- Morris, A.J.; Steele, J.; A White, D. The Oral Cleanliness and Periodontal Health of UK Adults in 1998. Br. Dent. J. 2001, 191, 186–192. [Google Scholar] [CrossRef]
- Axelsson, P.; Albandar, J.M.; Rams, T.E. Prevention and Control of Periodontal Diseases in Developing and Industrialized nations. Periodontol. 2000 2002, 29, 235–246. [Google Scholar] [CrossRef]
- Bakdash, B. Current patterns of oral Hygiene Product Use and Practices. Periodontol. 2000 1995, 8, 11–14. [Google Scholar] [CrossRef]
- Gontiya, G.; Galgali, S.R. Effect of Hyaluronan on Periodontitis: A Clinical and Histological Study. J. Indian Soc. Periodontol. 2012, 16, 184–192. [Google Scholar] [CrossRef]
- Rajan, P.; Baramappa, R.; Rao, N.M.; Pavaluri, A.K.; Rahaman, P.I. Hyaluronic Acid as an Adjunct to Scaling and Root Planing in Chronic Periodontitis. A Randomized Clinical Trail. J. Clin. Diagn. Res. 2014, 8, ZC11–ZC14. [Google Scholar] [CrossRef]
- Polepalle, T.; Srinivas, M.; Swamy, N.; Aluru, S.; Chakrapani, S.; Chowdary, B.A. Local Delivery of Hyaluronan 0.8% as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis: A Clinical and Microbiological Study. J. Indian Soc. Periodontol. 2015, 19, 37–42. [Google Scholar] [CrossRef]
- Johannsen, A.; Tellefsen, M.; Wikesjö, U.; Johannsen, G. Local Delivery of Hyaluronan as an Adjunct to Scaling and Root Planing in the Treatment of Chronic Periodontitis. J. Periodontol. 2009, 80, 1493–1497. [Google Scholar] [CrossRef] [PubMed]
- Bogaerde, L.V. Treatment of Infrabony Periodontal Defects with Esterified Hyaluronic Acid: Clinical Report of 19 Consecutive Lesions. Int. J. Periodontics Restor. Dent. 2009, 29, 315–323. [Google Scholar]
- Briguglio, F.; Briguglio, E.; Briguglio, R.; Cafiero, C.; Isola, G. Treatment of Infrabony Periodontal Defects Using a Resorbable Biopolymer of Hyaluronic Acid: A Randomized Clinical Trial. Quintessence Int. 2013, 44, 231–240. [Google Scholar] [CrossRef] [PubMed]
- Agarwal, A.; Gupta, N.D. Platelet-rich Plasma with Scaling and Root Planing: A Double-blind Split-mouth Randomized Study. J. Periodontol. Implant. Dent. 2014, 6, 35–39. [Google Scholar] [CrossRef]
- Tonetti, M.S.; Lang, N.P.; Cortellini, P.; Suvan, J.E.; Adriaens, P.; Dubravec, D.; Fonzar, A.; Fourmousis, I.; Mayfield, L.; Rossi, R.; et al. Enamel Matrix Proteins in the Regenerative Therapy of Deep Intrabony Defects. J. Clin. Periodontol. 2002, 29, 317–325. [Google Scholar] [CrossRef]
- Nyman, S.; Lindhe, J.; Karring, T.; Rylander, H. New Attachment Following Surgical Treatment of Human Periodontal Disease. J. Clin. Periodontol. 1982, 9, 290–296. [Google Scholar] [CrossRef]
- Liu, J.; Ruan, J.; Weir, M.D.; Ren, K.; Schneider, A.; Wang, P.; Oates, T.W.; Chang, X.; Xu, H.H.K. Periodontal Bone-Ligament-Cementum Regeneration via Scaffolds and Stem Cells. Cells 2019, 8, 537. [Google Scholar] [CrossRef]
- Szulc, M.; Zakrzewska, A.; Zborowski, J. Local Drug Delivery in Periodontitis Treatment: A Review of Contemporary Literature. Dent. Med. Probl. 2018, 55, 333–342. [Google Scholar] [CrossRef]
- Figuero, E.; Serrano, J.; Arweiler, N.B.; Auschill, T.M.; Gürkan, A.; Emingil, G. Supra and Subgingival Application of Antiseptics or Antibiotics During Periodontal Therapy. Periodontol. 2000 2023. [Google Scholar] [CrossRef]
- Sato, S.; Fonseca, M.J.V.; Del Ciampo, J.O.; Jabor, J.R.; Pedrazzi, V. Metronidazole-Containing Gel for the Treatment of Periodontitis: An in Vivo Evaluation. Braz. Oral Res. 2008, 22, 145–150. [Google Scholar] [CrossRef]
- Tilakaratne, A.; Soory, M. Anti-inflammatory Actions of Adjunctive Tetracyclines and Other Agents in Periodontitis and Associated Comorbidities. Open Dent. J. 2014, 8, 109–124. [Google Scholar] [CrossRef]
- Mailoa, J.; Lin, G.; Khoshkam, V.; MacEachern, M.; Chan, H.; Wang, H. Long-Term Effect of Four Surgical Periodontal Therapies and One Non-Surgical Therapy: A Systematic Review and Meta-Analysis. J. Periodontol. 2015, 86, 1150–1158. [Google Scholar] [CrossRef]
- Duane, B.; Yap, T.; Neelakantan, P.; Anthonappa, R.; Bescos, R.; McGrath, C.; McCullough, M.; Brookes, Z. Mouthwashes: Alternatives and Future Directions. Int. Dent. J. 2023, 73, S89–S97. [Google Scholar] [CrossRef]
- Di Stefano, M.; Santonocito, S.; Polizzi, A.; Mauceri, R.; Troiano, G.; Giudice, A.L.; Romano, A.; Mascitti, M.; Isola, G. A Reciprocal Link between Oral, Gut Microbiota during Periodontitis: The Potential Role of Probiotics in Reducing Dysbiosis-Induced Inflammation. Int. J. Mol. Sci. 2023, 24, 1084. [Google Scholar] [CrossRef]
- Serhan, C.N. Pro-Resolving Lipid Mediators are Leads for Resolution Physiology. Nature 2014, 510, 92–101. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Polizzi, A.; Leanza, Y.; Belmonte, A.; Grippaudo, C.; Leonardi, R.; Isola, G. Impact of Hyaluronic Acid and Other Re-Epithelializing Agents in Periodontal Regeneration: A Molecular Perspective. Int. J. Mol. Sci. 2024, 25, 12347. https://doi.org/10.3390/ijms252212347
Polizzi A, Leanza Y, Belmonte A, Grippaudo C, Leonardi R, Isola G. Impact of Hyaluronic Acid and Other Re-Epithelializing Agents in Periodontal Regeneration: A Molecular Perspective. International Journal of Molecular Sciences. 2024; 25(22):12347. https://doi.org/10.3390/ijms252212347
Chicago/Turabian StylePolizzi, Alessandro, Ylenia Leanza, Antonio Belmonte, Cristina Grippaudo, Rosalia Leonardi, and Gaetano Isola. 2024. "Impact of Hyaluronic Acid and Other Re-Epithelializing Agents in Periodontal Regeneration: A Molecular Perspective" International Journal of Molecular Sciences 25, no. 22: 12347. https://doi.org/10.3390/ijms252212347
APA StylePolizzi, A., Leanza, Y., Belmonte, A., Grippaudo, C., Leonardi, R., & Isola, G. (2024). Impact of Hyaluronic Acid and Other Re-Epithelializing Agents in Periodontal Regeneration: A Molecular Perspective. International Journal of Molecular Sciences, 25(22), 12347. https://doi.org/10.3390/ijms252212347